Skip to main content

Advertisement

SpringerLink
Log in

CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck

  • Review Article
  • Published:
European Archives of Oto-Rhino-Laryngology Aims and scope Submit manuscript

Abstract

Purpose

Addition of CDK4/6 inhibitors to a variety of established treatments in squamous cell carcinoma of the head and neck (SCCHN) has the potential to improve responses to other therapies and may help overcome treatment resistance. The SCCHN is a heterogeneous group of cancers of the oral cavity, the pharynx and the larynx with poor prognosis despite the aggressive multimodal therapies. In the past decade, significant advances were made in understanding of the molecular and genetic abnormalities leading to oncogenesis in SCCHN.

Recent findings

Besides EGFR targeting agents, antiangiogenic agents have been shown to produce antitumor activity in these tumors. The cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway regulates cellular proliferation by controlling the G1 to S cell cycle checkpoint. In SCCHN, the Rb pathway is frequently altered through amplification of CCND1 (cyclin D1) or deletion of CDKN2A (cyclin-dependent kinase inhibitor 2A) coding for p16INK4A, and thus promoting proliferation.

Summary

This article summarizes what we actually know of the place of CDK4/6 inhibitors in the therapeutic arsenal of SCCHN. CDK4/6 inhibitors could serve as a method to target these tumors, and both p16 loss and CCND1 amplification could be investigated as biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127. https://doi.org/10.1056/NEJMoa0802656

    Article  CAS  PubMed  Google Scholar 

  2. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G et al (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915–1928. https://doi.org/10.1016/S0140-6736(19)32591-7

    Article  CAS  PubMed  Google Scholar 

  3. Cohen EEW, Soulières D, Tourneau CL, Dinis J, Licitra L, Ahn M-J et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393:156–167. https://doi.org/10.1016/S0140-6736(18)31999-8

    Article  CAS  PubMed  Google Scholar 

  4. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867. https://doi.org/10.1056/NEJMoa1602252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157–1160. https://doi.org/10.1126/science.1208130

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Network CGA (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582. https://doi.org/10.1038/nature14129

    Article  CAS  Google Scholar 

  7. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM (2008) Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res Off J Am Assoc Cancer Res 14:366–369. https://doi.org/10.1158/1078-0432.CCR-07-1402

    Article  CAS  Google Scholar 

  8. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR (2014) APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833–1841. https://doi.org/10.1016/j.celrep.2014.05.012

    Article  CAS  PubMed  Google Scholar 

  9. Zevallos JP, Yim E, Brennan P, Liu AY, Taylor JM, Weissler M et al (2016) Molecular profile of human papillomavirus-positive oropharyngeal squamous cell carcinoma stratified by smoking status. Int J Radiat Oncol Biol Phys 94:864. https://doi.org/10.1016/j.ijrobp.2015.12.022

    Article  Google Scholar 

  10. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783. https://doi.org/10.1200/JCO.2005.03.7689

    Article  CAS  PubMed  Google Scholar 

  11. Baker SJ, Reddy EP (2012) CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 3:658–669. https://doi.org/10.1177/1947601913478972

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Paternot S, Bockstaele L, Bisteau X, Kooken H, Coulonval K, Roger PP (2010) Rb inactivation in cell cycle and cancer: the puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase. Cell Cycle Georget Tex 9:689–699. https://doi.org/10.4161/cc.9.4.10611

    Article  CAS  Google Scholar 

  13. Leemans CR, Braakhuis BJM, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9–22. https://doi.org/10.1038/nrc2982

    Article  CAS  PubMed  Google Scholar 

  14. Wreesmann VB, Singh B (2005) Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol 34:449–459. https://doi.org/10.1111/j.1600-0714.2005.00343.x

    Article  CAS  Google Scholar 

  15. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM et al (2013) Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3:770–781. https://doi.org/10.1158/2159-8290.CD-12-0537

    Article  CAS  PubMed  Google Scholar 

  16. Feng Z, Guo W, Zhang C, Xu Q, Zhang P, Sun J et al (2011) CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma. PLoS ONE 6:e26399. https://doi.org/10.1371/journal.pone.0026399

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35. https://doi.org/10.1056/NEJMoa0912217

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21:1510–1517. https://doi.org/10.1038/sj.onc.1205214

    Article  CAS  PubMed  Google Scholar 

  19. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427–1438

    CAS  PubMed  Google Scholar 

  20. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ et al (2009) PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res BCR 11:R77. https://doi.org/10.1186/bcr2419

    Article  CAS  PubMed  Google Scholar 

  21. Baughn LB, Di Liberto M, Wu K, Toogood PL, Louie T, Gottschalk R et al (2006) A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res 66:7661–7667. https://doi.org/10.1158/0008-5472.CAN-06-1098

    Article  CAS  PubMed  Google Scholar 

  22. Flaherty KT, Lorusso PM, Demichele A, Abramson VG, Courtney R, Randolph SS et al (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 18:568–576. https://doi.org/10.1158/1078-0432.CCR-11-0509

    Article  CAS  Google Scholar 

  23. Schwartz GK, LoRusso PM, Dickson MA, Randolph SS, Shaik MN, Wilner KD et al (2011) Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:1862–1868. https://doi.org/10.1038/bjc.2011.177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D et al (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res Off J Am Assoc Cancer Res 19:6173–6182. https://doi.org/10.1158/1078-0432.CCR-13-1675

    Article  CAS  Google Scholar 

  25. Infante JR, Cassier PA, Gerecitano JF, Witteveen PO, Chugh R, Ribrag V et al (2016) A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res Off J Am Assoc Cancer Res 22:5696–5705. https://doi.org/10.1158/1078-0432.CCR-16-1248

    Article  CAS  Google Scholar 

  26. Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck|Annals of Oncology|Oxford Academic n.d. https://academic.oup.com/annonc/article/27/suppl_6/1002P/2799758. Accessed 18 Mar 2019

  27. Ku BM, Yi SY, Koh J, Bae Y-H, Sun J-M, Lee S-H et al (2016) The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget 7:14803–14813. https://doi.org/10.18632/oncotarget.7543

    Article  PubMed  PubMed Central  Google Scholar 

  28. Gelbert LM, Cai S, Lin X, Sanchez-Martinez C, Del Prado M, Lallena MJ et al (2014) Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 32:825–837. https://doi.org/10.1007/s10637-014-0120-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S et al (2013) CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle Georget Tex 12:1091–1104. https://doi.org/10.4161/cc.24091

    Article  CAS  Google Scholar 

  30. Franco J, Witkiewicz AK, Knudsen ES (2014) CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 5:6512–6525. https://doi.org/10.1863/oncotarget.2270

    Article  PubMed  PubMed Central  Google Scholar 

  31. McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E et al (2012) CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle Georget Tex 11:2747–2755. https://doi.org/10.4161/cc.21127

    Article  CAS  Google Scholar 

  32. Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol Off J Am Soc Clin Oncol 23:9408–9421. https://doi.org/10.1200/JCO.2005.01.5594

    Article  CAS  Google Scholar 

  33. Clark AS, O’Dwyer PJ, Heitjan D, Lal P, Feldman MD, Gallagher M et al (2014) A phase I trial of palbociclib and paclitaxel in metastatic breast cancer. J Clin Oncol 32:527–527. https://doi.org/10.1200/jco.2014.32.15_suppl.527

    Article  Google Scholar 

  34. Ogawa K, Yoshioka Y, Isohashi F, Seo Y, Yoshida K, Yamazaki H (2013) Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 33:747–754

    CAS  PubMed  Google Scholar 

  35. Hagen KR, Zeng X, Lee M-Y, Kahn ST, Pitner MKH, Zaky SS et al (2013) Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Div 8:10. https://doi.org/10.1186/1747-1028-8-10

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Han YK, Lee JH, Park GY, Chun SH, Han JY, Kim SD et al (2013) A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. Biochem Biophys Res Commun 430:1329–1333. https://doi.org/10.1016/j.bbrc.2012.10.119

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology-Radiotherapy, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, 94805, Villejuif, France

    Camelia Billard-Sandu, Yun-Gan Tao, Gabriela Dumitrescu & Eric Deutsch

  2. Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France

    Marie-Paule Sablin

  3. Oncology Unit, André Mignot Hospital, Versailles, France

    David Billard

Authors
  1. Camelia Billard-Sandu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yun-Gan Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie-Paule Sablin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gabriela Dumitrescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Billard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eric Deutsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Camelia Billard-Sandu.

Ethics declarations

Conflict of interest

Camelia Billard-Sandu: travel fee: Merck Serono. Yun Gan Tao: travel fee: Merck Serono, MSD; advisory: MSD; research for Institution: MSD, Pfizer, Debiopharma. Marie-Paule Sablin: personal fees: Servier. Gabriela Dumitrescu: none declared. David Billard: none declared. Eric Deutsch: grants from Servier, BMS, MSD; grants and personal fees from Roche; Astrazeneca, Merck Serono, Boerhinger; personal fees from: Amgen, Accuray.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Billard-Sandu, C., Tao, YG., Sablin, MP. et al. CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol 277, 1273–1280 (2020). https://doi.org/10.1007/s00405-020-05891-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00405-020-05891-2

Keywords

Search

Navigation